Treatment of Familial Mediterranean Fever Flare
Start or optimize colchicine immediately—increase the dose within the recommended range (up to 2 mg/day in children, 3 mg/day in adults) if already on treatment, and for colchicine-resistant patients, add IL-1 inhibitors as the preferred biologic therapy. 1
Immediate Management Algorithm
First-Line: Colchicine Optimization
If not yet on colchicine: Start immediately at diagnosis, even during an acute flare 1
- Children <5 years: ≤0.5-0.6 mg/day
- Children 5-10 years: 0.5-1.2 mg/day
- Children >10 years and adults: 1.0-1.8 mg/day initially
If already on colchicine: Increase the dose gradually (no more frequently than weekly) up to maximum tolerated dose 1
- Maximum 2 mg/day in children
- Maximum 3 mg/day in adults
- Can be given as single or divided doses (single dose may cause more GI intolerance) 1
Critical caveat: Before increasing colchicine, verify adherence—non-adherence is a common cause of persistent attacks, not true resistance 1. The 2025 EULAR/PRES guidelines explicitly emphasize this must be confirmed before escalating therapy.
Defining Treatment Failure
Colchicine resistance is defined as: 1
- ≥1 attack per month over a 3-month period, OR
- Persistent laboratory inflammation between attacks (elevated CRP, SAA, ESR)
- Despite adherence to maximum tolerated colchicine dose
Second-Line: Biologic Therapy
For adherent patients with colchicine resistance or intolerance, add IL-1 inhibitors (highest level of evidence with 6 RCTs supporting this approach): 1
Preferred IL-1 inhibitor options:
- Anakinra: 100 mg/day or 2 mg/kg subcutaneously daily
- Canakinumab: 150-300 mg or 2-4 mg/kg subcutaneously every 4-8 weeks
- Rilonacept: 2.2 mg/kg (max 160 mg) subcutaneously weekly
Alternative biologics (require expert consultation, not approved for FMF):
- Tocilizumab (anti-IL-6): 162 mg or 4-8 mg/kg weekly subcutaneously
- Tofacitinib: 5 mg twice daily orally
Adjunctive Symptomatic Treatment
While the guidelines focus on disease-modifying therapy, for acute symptom relief during flares: 1
- NSAIDs: May be used for mild cases, particularly exertional leg pain
- Corticosteroids: Reserved for protracted febrile myalgia (requires expert consultation) 1
- Avoid: Intravenous colchicine is explicitly discouraged 1
Real-World Patient Behavior
A 2025 study of 258 FMF patients revealed that 93% use mitigation strategies during attacks, with ED admission (19.8%) and colchicine dose increase (18.2%) being most common 2. However, self-directed colchicine dose increases during flares are not formally recommended in guidelines—the focus is on maintaining adequate prophylactic dosing to prevent attacks altogether.
Monitoring During and After Flares
Assess response every 3-6 months (more frequently if disease uncontrolled): 1
- Attack frequency and duration
- Inflammatory markers: CRP, SAA, ESR, fibrinogen
- Complete blood count and liver function tests (colchicine toxicity monitoring)
- Quality of life assessment
Treatment targets:
- Clinical remission: Attack-free or minimal attacks
- Biochemical remission: Normalization of acute phase reactants between attacks
- Prevention of AA amyloidosis (the critical long-term complication) 3
Special Considerations
Chronic musculoskeletal involvement (spondyloarthropathy): May require additional DMARDs beyond colchicine and IL-1 inhibitors, as these features can be less responsive to standard FMF therapy 1
Tapering biologics: After 6-12 months of clinical and biochemical remission on biologics, consider decreasing dose or increasing dosing intervals 1
Evidence Strength
The 2025 EULAR/PRES guidelines represent the most current, high-quality evidence 1. The recommendation for colchicine has increased evidence level based on updated systematic reviews, and IL-1 inhibitors now have robust RCT support (6 trials) compared to only 2 RCTs for IL-6 inhibitors 1. Older evidence from 2013-2018 4, 5 is superseded by these 2025 guidelines, though the core principle of colchicine as first-line therapy has remained consistent for decades 6, 3.
The critical paradigm shift: Modern FMF management is prophylactic and treat-to-target, not reactive treatment of individual flares. The goal is complete attack prevention and elimination of subclinical inflammation to prevent amyloidosis.